Lutathera

Active Ingredient(s): Lutetium Lu 177 Dotatate
FDA Approved: * January 26, 2018
Pharm Company: * ADVANCED ACCELERATOR APPLICATIONS USA INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Lutathera Overview

DOTA-TATE (DOTATATE,[1] DOTA-octreotate, oxodotreotide, DOTA-(Tyr3)-octreotate,[2] and DOTA-0-Tyr3-Octreotate) is an amino acid peptide, with a covalently bonded DOTA bifunctional chelator. DOTA-TATE can be bound with radionuclides such as gallium-68 and lutetium-177 to form radiopharmaceuticals for PET imaging or radionuclide therapy. 177Lu DOTA-TATE therapy is a form of peptide receptor radionuclide therapy (PRRT) which targets somatostatin receptors (SSR).&a...

Read more Lutathera Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/DOTA-TATE

Recent Lutathera Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Lutathera: (1 result)

Sorted by National Drug Code

• 69488-003 Lutathera 10 mci/Ml Intravenous Injection by Advanced Accelerator Applications USA, Inc

Other drugs which contain Lutetium Lu 177 Dotatate or a similar ingredient: (1 result)

• LUTETIUM LU 177 DOTATATE